The majority of CRC tumors are driven by the activation of oncogenic KRAS, BRAF, and PIK3CA mutations and in-activation mutations of the tumor suppressor TP53, which have been strongly linked to metabolic reprogramming in CRC [3,4,5] and drug resistance [6]. The gene discussed is KRAS; the disease is colorectal carcinoma.